v3.7.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
NET REVENUE    
Clinical testing $ 56,690 $ 54,622
Pharma Services 4,986 5,082
Total Revenue 61,676 59,704
COST OF REVENUE 34,480 32,531
GROSS MARGIN 27,196 27,173
Operating expenses:    
General and administrative 20,801 18,005
Research and development 862 1,446
Sales and marketing 5,648 5,800
Total operating expenses 27,311 25,251
INCOME (LOSS) FROM OPERATIONS (115) 1,922
Interest expense, net 1,364 1,593
Income (loss) before taxes (1,479) 329
Income tax (benefit) expense (825) 174
NET INCOME (LOSS) (654) 155
Deemed dividends on preferred stock 894 1,840
Amortization of preferred stock beneficial conversion feature 1,672 3,727
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (3,220) $ (5,412)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS    
Basic $ (0.04) $ (0.07)
Diluted $ (0.04) $ (0.07)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
Basic 78,650 76,068
Diluted 78,650 76,068

Source